Want to see HK:1789 full AI Analyst Report?
1789 Stock Chart & Stats
HK$5.91
-HK$0.05(-1.15%)
At close: 4:00 PM EST
HK$5.91
-HK$0.05(-1.15%)
Day’s Range― - ―
52-Week RangeHK$4.75 - HK$7.15
Previous CloseN/A
Volume3.85M
Average Volume (3M)4.30M
Market Cap
HK$6.19B
Enterprise ValueHK$4.91K
Total Cash (Recent Filing)HK$1.47B
Total Debt (Recent Filing)HK$144.79M
Price to Earnings (P/E)15.8
Beta1.08
Next Earnings
Sep 02, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend Yield2.14%
Share Statistics
EPS (TTM)0.30
Shares Outstanding1,124,616,700
10 Day Avg. Volume3,969,892
30 Day Avg. Volume4,297,109
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)1.97
Price to Sales (P/S)3.87
P/FCF Ratio18.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.37
Revenue Forecast (FY)HK$1.65B
Bulls Say, Bears Say
Bulls Say
High Profitability MarginsSustained high gross and operating margins indicate durable product-level economics and pricing power in joint-replacement implants. These margins support reinvestment in R&D and sales, buffer against cost shocks, and reflect a structurally advantaged product portfolio that can fund long-term growth initiatives.
Very Conservative Balance SheetExtremely low leverage provides substantial financial flexibility: ability to invest in new products, absorb procedure volume downturns, and avoid refinancing risk. A strong equity base supports capital allocation choices and reduces vulnerability to cyclical pressures in healthcare procurement cycles.
Material Free Cash Flow GenerationMeaningful and growing free cash flow in 2025 improves capacity to fund capex, product development, and shareholder returns without relying on debt. Consistent FCF coverage of net income enhances earnings quality and underpins sustainable investment in sales and manufacturing scale over the medium term.
Bears Say
Cash-Flow VolatilityLarge swings in operating and free cash flow reduce predictability of internal funding for growth and increase reliance on timing of receivables, inventory or one-off items. This volatility can constrain multi-year planning, raise financing costs, and limit consistent reinvestment despite strong reported profits.
Revenue Growth InconsistencyIrregular top-line progression signals uneven adoption or exposure to fluctuating procedure volumes and tender cycles. Persistent growth volatility hampers scale benefits, complicates long-range capacity and R&D planning, and risks ceding share to competitors during slower periods.
Dependence On Institutional ProcurementHeavy reliance on hospital tenders and surgeon adoption makes revenue sensitive to institutional buying cycles, pricing pressure and reimbursement shifts. Structurally, this exposure can compress margins and slow durable market share gains absent differentiated service, exclusive contracts, or broader channel diversification.
AK Medical Holdings Ltd. News
1789 FAQ
What was AK Medical Holdings Ltd.’s price range in the past 12 months?
AK Medical Holdings Ltd. lowest stock price was HK$4.75 and its highest was HK$7.15 in the past 12 months.
What is AK Medical Holdings Ltd.’s market cap?
AK Medical Holdings Ltd.’s market cap is HK$6.19B.
When is AK Medical Holdings Ltd.’s upcoming earnings report date?
AK Medical Holdings Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 31 days.
How were AK Medical Holdings Ltd.’s earnings last quarter?
AK Medical Holdings Ltd. released its earnings results on Mar 25, 2026. The company reported HK$0.186 earnings per share for the quarter, beating the consensus estimate of HK$0.174 by HK$0.012.
Is AK Medical Holdings Ltd. overvalued?
According to Wall Street analysts AK Medical Holdings Ltd.’s price is currently Overvalued.
Does AK Medical Holdings Ltd. pay dividends?
AK Medical Holdings Ltd. pays a Annually dividend of HK$0.118 which represents an annual dividend yield of 2.14%. See more information on AK Medical Holdings Ltd. dividends here
What is AK Medical Holdings Ltd.’s EPS estimate?
AK Medical Holdings Ltd.’s EPS estimate is 0.2.
How many shares outstanding does AK Medical Holdings Ltd. have?
AK Medical Holdings Ltd. has 1,124,616,700 shares outstanding.
What happened to AK Medical Holdings Ltd.’s price movement after its last earnings report?
AK Medical Holdings Ltd. reported an EPS of HK$0.186 in its last earnings report, beating expectations of HK$0.174. Following the earnings report the stock price went up 2.634%.
Which hedge fund is a major shareholder of AK Medical Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:1789
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AK Medical Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.55%
12-Months-Change
Fundamentals
Return on Equity
2.14%
Trailing 12-Months
Asset Growth
14.93%
Trailing 12-Months
Company Description
AK Medical Holdings Ltd.
AK Medical Holdings Limited, an investment holding enterprise, specializes in the research, development, production, and worldwide commercialization of orthopedic joint implants and related medical devices under the AK Medical brand. Its comprehensive product offerings encompass conventional knee, hip, and spine replacement implants, as well as advanced 3D-printed solutions like hip implants, artificial vertebral bodies, and spinal interbody cages. The company further expands its operations by distributing orthopedic products from third-party manufacturers and by fabricating surgical instruments and medical irrigators. Its diverse client base spans distributors, hospitals, physicians, surgeons, and directly serves patients. Established in Beijing, People's Republic of China, in 2003, AK Medical Holdings Limited functions as a subsidiary of Ximalaya Limited.
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
MicroPort CardioFlow Medtech Corp.
―
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
―
Venus Medtech (Hangzhou), Inc. Class H
―